Trial · NCT04598477
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE) | Efgartigimod-efgartigimod PH20 SC | Treatment-Emergent Adverse Event (TEAE) | 116.4 | number of events x 100/PYFU | |
| Incidence of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE) | Placebo-efgartigimod PH20 SC | Treatment-Emergent Adverse Event (TEAE) | 113.0 | number of events x 100/PYFU | |
| Incidence of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE) | Efgartigimod-efgartigimod PH20 SC | Adverse Event of Special Interest (AESI) | 72.0 | number of events x 100/PYFU | |
| Incidence of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE) | Placebo-efgartigimod PH20 SC | Adverse Event of Special Interest (AESI) | 69.3 | number of events x 100/PYFU | |
| Incidence of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE) | Efgartigimod-efgartigimod PH20 SC | Serious Adverse Event (SAE) | 24.5 | number of events x 100/PYFU | |
| Incidence of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE) | Placebo-efgartigimod PH20 SC | Serious Adverse Event (SAE) | 14.6 | number of events x 100/PYFU | |
| Proportion of Participants With Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) Who Achieve CRmin | Efgartigimod-efgartigimod PH20 SC | 55 | Participants | ||
| Proportion of Participants With Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) Who Achieve CRmin | Placebo-efgartigimod PH20 SC | 26 | Participants | ||
| Proportion of Participants With Pemphigus Vulgaris (PV) Who Achieve CRmin | Efgartigimod-efgartigimod PH20 SC | 47 | Participants | ||
| Proportion of Participants With Pemphigus Vulgaris (PV) Who Achieve CRmin | Placebo-efgartigimod PH20 SC | 22 | Participants | ||
| Time to DC in Participants With PV and PF | Efgartigimod-efgartigimod PH20 SC | 8.5 | 95% Confidence Interval 8.0 to 15.0 | days | |
| Time to DC in Participants With PV and PF | Placebo-efgartigimod PH20 SC | 15.0 | 95% Confidence Interval 8.0 to 22.0 | days | |
| Time to CR in Participants With PV and PF | Efgartigimod-efgartigimod PH20 SC | 66.0 | 95% Confidence Interval 43.0 to 182.0 | Days | |
| Time to CR in Participants With PV and PF | Placebo-efgartigimod PH20 SC | 71.0 | 95% Confidence Interval 41.0 to 100.0 | Days | |
| Time to CRmin in Participants With PV and PF | Efgartigimod-efgartigimod PH20 SC | 229.0 | 95% Confidence Interval 161.0 to NA | days | |
| Time to CRmin in Participants With PV and PF | Placebo-efgartigimod PH20 SC | 169.0 | 95% Confidence Interval 141.0 to 322.0 | days | |
| Time to CRoff in Participants With PV and PF | Efgartigimod-efgartigimod PH20 SC | NA | 95% Confidence Interval NA to NA | days | |
| Time to CRoff in Participants With PV and PF | Placebo-efgartigimod PH20 SC | NA | 95% Confidence Interval NA to NA | days | |
| Time to Flare After CRmin in Participants With PV and PF | Efgartigimod-efgartigimod PH20 SC | 339.0 | 95% Confidence Interval 223.0 to NA | days | |
| Time to Flare After CRmin in Participants With PV and PF | Placebo-efgartigimod PH20 SC | 168.0 | 95% Confidence Interval 64.0 to NA | days |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04598477/results